PEPG vs. TRDA, CRBP, BMEA, TBPH, MRSN, MREO, SLRN, ANNX, LXRX, and AMRN
Should you be buying PepGen stock or one of its competitors? The main competitors of PepGen include Entrada Therapeutics (TRDA), Corbus Pharmaceuticals (CRBP), Biomea Fusion (BMEA), Theravance Biopharma (TBPH), Mersana Therapeutics (MRSN), Mereo BioPharma Group (MREO), Acelyrin (SLRN), Annexon (ANNX), Lexicon Pharmaceuticals (LXRX), and Amarin (AMRN). These companies are all part of the "pharmaceutical preparations" industry.
Entrada Therapeutics (NASDAQ:TRDA) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Comparatively, 4.0% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Entrada Therapeutics had 8 more articles in the media than PepGen. MarketBeat recorded 11 mentions for Entrada Therapeutics and 3 mentions for PepGen. PepGen's average media sentiment score of 1.11 beat Entrada Therapeutics' score of 0.30 indicating that Entrada Therapeutics is being referred to more favorably in the media.
Entrada Therapeutics has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, PepGen has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500.
PepGen has a net margin of 0.00% compared to PepGen's net margin of -5.18%. PepGen's return on equity of -2.89% beat Entrada Therapeutics' return on equity.
PepGen received 1 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. Likewise, 85.71% of users gave PepGen an outperform vote while only 73.33% of users gave Entrada Therapeutics an outperform vote.
Entrada Therapeutics currently has a consensus target price of $21.00, suggesting a potential upside of 46.44%. PepGen has a consensus target price of $24.67, suggesting a potential upside of 76.06%. Given Entrada Therapeutics' higher possible upside, analysts clearly believe PepGen is more favorable than Entrada Therapeutics.
Entrada Therapeutics has higher revenue and earnings than PepGen. Entrada Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.
Summary
Entrada Therapeutics beats PepGen on 9 of the 15 factors compared between the two stocks.
Get PepGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PEPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PEPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
